Drug repositioning for Alzheimer's disease

被引：220

作者：

Corbett, Anne ^{[1
]}

Pickett, James ^{[2
]}

Burns, Alistair ^{[3
]}

Corcoran, Jonathan ^{[1
]}

Dunnett, Stephen B. ^{[4
]}

Edison, Paul ^{[5
]}

Hagan, Jim J. ^{[6
]}

Holmes, Clive ^{[7
]}

Jones, Emma ^{[1
]}

Katona, Cornelius ^{[8
]}

Kearns, Ian ^{[9
]}

Kehoe, Patrick ^{[10
]}

Mudher, Amrit ^{[11
]}

Passmore, Anthony ^{[12
]}

Shepherd, Nicola ^{[13
]}

Walsh, Frank ^{[14
]}

Ballard, Clive ^{[1
]}

机构：

[1] Kings Coll London, Wolfson Ctr Age Related Dis, London SE1 1UL, England

[2] UK Alzheimers Soc, London E1W 1LB, England

[3] Univ Manchester, Manchester M13 9PT, Lancs, England

[4] Cardiff Univ, Brain Repair Grp, Sch Biosci, Cardiff CF10 3AX, S Glam, Wales

[5] Univ London Imperial Coll Sci Technol & Med, London W12 0NN, England

[6] Kings Coll London, Global Med Excellence Cluster GMEC, London SE1 1UL, England

[7] Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England

[8] UCL, Mental Hlth Sci Unit, Fac Brain Sci, London WC1E 6BT, England

[9] AstraZeneca, London W2 6BD, England

[10] Univ Bristol, John James Labs, Frenchay Hosp, Bristol BS16 1LE, Avon, England

[11] Univ Southampton, Southampton SO17 1BJ, Hants, England

[12] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT9 7BL, Antrim, North Ireland

[13] Wellcome Trust Res Labs, London NW1 2BE, England

[14] Kings Coll London, Inst Psychiat, London SE1 1UL, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2012年 / 11卷 / 11期

关键词：

GLUCAGON-LIKE PEPTIDE-1; CEREBRAL-BLOOD-FLOW; RENIN-ANGIOTENSIN SYSTEM; SIMPLEX-VIRUS TYPE-1; BETA-AMYLOID PROTEIN; NERVE GROWTH-FACTOR; RETINOIC ACID; MOUSE MODEL; COGNITIVE IMPAIRMENT; HUNTINGTONS-DISEASE;

D O I：

10.1038/nrd3869

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. Given the recent failures of various novel disease-modifying therapies in clinical trials, a complementary strategy based on repositioning drugs that are approved for other indications could be attractive. Indeed, a substantial body of preclinical work indicates that several classes of such drugs have potentially beneficial effects on Alzheimer's-like brain pathology, and for some drugs the evidence is also supported by epidemiological data or preliminary clinical trials. Here, we present a formal consensus evaluation of these opportunities, based on a systematic review of published literature. We highlight several compounds for which sufficient evidence is available to encourage further investigation to clarify an optimal dose and consider progression to clinical trials in patients with Alzheimer's disease.

引用

页码：833 / 846

页数：14

共 139 条

[1] Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies [J].

Anderson, Craig ;

Teo, Koon ;

Gao, Peggy ;

Arima, Hisatomi ;

Dans, Antonio ;

Unger, Thomas ;

Commerford, Patrick ;

Dyal, Leanne ;

Schumacher, Helmut ;

Pogue, Janice ;

Paolasso, Ernesto ;

Holwerda, Nicolaas ;

Chazova, Irina ;

Binbrek, Azan ;

Young, James ;

Yusuf, Salim .

LANCET NEUROLOGY, 2011, 10 (01) :43-53

[2] L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease [J].

Anekonda, Thimmappa S. ;

Quinn, Joseph F. ;

Harris, Christopher ;

Frahler, Kate ;

Wadsworth, Teri L. ;

Woltjer, Randall L. .

NEUROBIOLOGY OF DISEASE, 2011, 41 (01) :62-70

[3] Drug repositioning: Identifying and developing new uses for existing drugs [J].

Ashburn, TT ;

Thor, KB .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683

[4] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].

Astrup, Arne ;

Rossner, Stephan ;

Van Gaal, Luc ;

Rissanen, Aila ;

Niskanen, Leo ;

Al Hakim, Mazin ;

Madsen, Jesper ;

Rasmussen, Mads F. ;

Lean, Michael E. J. .

LANCET, 2009, 374 (9701) :1606-1616

[5] Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier [J].

Bachmeier, Corbin ;

Beaulieu-Abdelahad, David ;

Mullan, Michael ;

Paris, Daniel .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 659 (2-3) :124-129

[6] Insulin Resistance and Alzheimer-like Reductions in Regional Cerebral Glucose Metabolism for Cognitively Normal Adults With Prediabetes or Early Type 2 Diabetes [J].

Baker, Laura D. ;

Cross, Donna J. ;

Minoshima, Satoshi ;

Belongia, Dana ;

Watson, Stennis ;

Craft, Suzanne .

ARCHIVES OF NEUROLOGY, 2011, 68 (01) :51-57

[7] Alzheimer's disease [J].

Ballard, Clive ;

Gauthier, Serge ;

Corbett, Anne ;

Brayne, Carol ;

Aarsland, Dag ;

Jones, Emma .

LANCET, 2011, 377 (9770) :1019-1031

[8]

Ballard C, 2011, EXPERT REV NEUROTHER, V11, P327, DOI [10.1586/ern.11.13, 10.1586/ERN.11.13]

[9] Neuroprotection in Huntingtons disease:: a 2-year study on minocycline [J].

Bonelli, RM ;

Hödl, AK ;

Hofmann, P ;

Kapfhammer, HP .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (06) :337-342

[10] Minocycline for Huntington's disease: An open label study [J].

Bonelli, RM ;

Heuberger, C ;

Reisecker, F .

NEUROLOGY, 2003, 60 (05) :883-884

← 1 2 3 4 5 6 7 8 9 10 →